Novartis to buy France’s Advanced Accelerator for $3.9 bln

NovartisZURICH, Oct 30 (Reuters) – Swiss drugmaker Novartis on Monday said it was buying France’s Advanced Accelerator Applications (AAA) in a $3.9 billion cash deal to strengthen the oncology portfolio at the world’s biggest maker of prescription medicines.

Basel-based Novartis is offering $41 per ordinary share and $82 per American depositary share for AAA, which makes radiopharmaceuticals including the product Lutathera that are used for both diagnosis and therapy. (Reporting by John Miller; Editing by Michael Shields)